Anti-interleukin-6 Receptor Antibody (Tocilizumab) Treatment of Multicentric Castleman's Disease

Masashi Matsuyama; Takeshi Suzuki; Hiroto Tsuboi; Satoshi Ito; Mizuko Mamura; Daisuke Goto; Isao Matsumoto; Akito Tsutsumi; Takayuki Sumida

doi:10.2169/internalmedicine.46.6262

CASE REPORTS

Anti-interleukin-6 Receptor Antibody (Tocilizumab) Treatment of Multicentric Castleman's Disease

Masashi Matsuyama, Takeshi Suzuki, Hiroto Tsuboi, Satoshi Ito, Mizuko Mamura, Daisuke Goto, Isao Matsumoto, Akito Tsutsumi, Takayuki Sumida

Author information

Masashi Matsuyama
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Takeshi Suzuki
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Hiroto Tsuboi
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Satoshi Ito
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Mizuko Mamura
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Daisuke Goto
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Isao Matsumoto
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Akito Tsutsumi
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Takayuki Sumida
Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba

Keywords: multicentric Castleman's disease, anti-interleukin-6 receptor antibody, tocilizumab

JOURNAL OPEN ACCESS

2007 Volume 46 Issue 11 Pages 771-774

DOI https://doi.org/10.2169/internalmedicine.46.6262

Details

Abstract

We report three cases of multicentric Castleman's disease (MCD) successfully treated with anti-interleukin-6 receptor antibody (tocilizumab). Tocilizumab was administered intravenously at a dose of 8 mg/kg every 2 weeks. In each case, tocilizumab alleviated symptoms, including generalized fatigue, pyrexia, and alleviated biochemical abnormalities, including anemia, hypoalbuminemia, hypergammaglobulinemia, and increased C-reactive protein (CRP). Side effects included hypercholesterolemia, acute pyelonephritis, mild inflammation of the parotid glands, and upper respiratory system inflammation. Other severe side effects were not observed. These results indicate that tocilizumab is effective for the treatment of MCD. This is the first report on tocilizumab efficacy for Castleman's disease after approval for use for Castleman's disease.

Corresponding author

Register with J-STAGE for free!